10-K: Xilio Therapeutics Reports Reduced Losses, Strategic Progress in 2025

Sentiment:

Annual Report 23 March 2026 7:40 AM

📋All filings for Xilio Therapeutics, INC

Xilio Therapeutics, a clinical-stage biotechnology company, reported a significant reduction in net losses for 2025, driven by increased collaboration revenue and strategic advancements in its immuno-oncology pipeline.

Capital raiseThe company received net proceeds of approximately $37.3 million in Q1 2026 from a follow-on offering of prefunded warrants.There is a potential to receive up to $36.2 million in additional gross proceeds in H2 2026 if all outstanding Series C common stock warrants are exercised at their current exercise price of $10.50 per warrant.The company explicitly states that its existing cash and cash equivalents will not be sufficient to complete development of any current or future product candidates, and it will require additional capital in the future through public or private equity offerings, debt, collaborations, licensing arrangements, or other sources.

Better than expectedNet loss decreased significantly from $58.2 million in 2024 to $35.0 million in 2025, indicating improved financial efficiency or increased revenue generation.Total revenue increased by $37.4 million, primarily driven by collaboration and license agreements, which is a positive indicator of strategic partnership success and funding.Cash and cash equivalents increased to $137.5 million by the end of 2025, and further bolstered by $37.3 million net proceeds in Q1 2026, extending the cash runway through the end of 2027, which is a stronger liquidity position than many early-stage biotech companies.

Summary

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing masked immuno-oncology (I-O) therapies designed to selectively activate within the tumor microenvironment, aiming for durable efficacy without severe systemic side effects.
The company reported a net loss of $35.0 million for the year ended December 31, 2025, a significant improvement from the $58.2 million net loss in 2024.
Total revenue increased substantially to $43.8 million in 2025 from $6.3 million in 2024, primarily due to collaboration and license agreements with AbbVie and Gilead.
Research and development expenses increased to $56.0 million in 2025 from $41.2 million in 2024, reflecting increased clinical development activities for efarindodekin alfa and IND-enabling studies for XTX501, partially offset by decreased costs for XTX202 due to discontinued investment.
General and administrative expenses rose to $29.7 million in 2025 from $24.8 million in 2024, mainly due to higher personnel-related costs and increased legal and professional fees.
As of December 31, 2025, cash and cash equivalents stood at $137.5 million, with an accumulated deficit of $418.8 million.
The company anticipates its existing cash and cash equivalents, combined with recent financing and milestone payments, will fund operating expenses and capital expenditure requirements through the end of 2027.
A 1-for-14 reverse stock split was effected on March 13, 2026, to help regain compliance with Nasdaq's minimum bid price requirement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the significant reduction in net losses and substantial increase in collaboration revenue, indicating successful strategic partnerships and pipeline advancement. While the company still faces significant capital needs and competitive risks, the extended cash runway and promising early clinical data for efarindodekin alfa provide a strong foundation for future development.

Positives

Net loss significantly reduced to $35.0 million in 2025 from $58.2 million in 2024, indicating improved financial performance.
Collaboration and license revenue surged by $37.4 million, reaching $43.8 million in 2025, primarily from agreements with AbbVie and Gilead.
Received a $5.0 million development milestone payment related to the AbbVie collaboration program in Q1 2026.
Received a $17.5 million development milestone payment from Gilead in Q3 2025 for efarindodekin alfa.
Phase 1 clinical trial data for efarindodekin alfa (masked IL-12) demonstrated encouraging anti-tumor activity, including two partial responses in advanced solid tumors (HPV-negative head and neck squamous cell carcinoma and uveal melanoma), and was generally well-tolerated at doses over 100-fold greater than the maximum tolerated dose of recombinant human IL-12.
XTX501 (bispecific PD-1 / masked IL-2) is advancing towards an IND application in mid-2026 and a Phase 1 trial in H2 2026, with initial Phase 1 data expected in H2 2027.
Wholly-owned masked T cell engager programs targeting PSMA+STEAP1 and CLDN18.2 are advancing into IND-enabling studies with IND applications planned for 2027.
The company's clinically-validated masking technology has enabled top-tier strategic partnerships with AbbVie and Gilead.
Successful follow-on offerings in June 2025 and February 2026, along with warrant exercises, provided significant capital inflows.

Negatives

The company has incurred significant operating losses since inception, with an accumulated deficit of $418.8 million as of December 31, 2025.
Operating expenses increased by $18.8 million in 2025, primarily due to higher research and development costs.
The company does not expect to generate any revenue from product sales for several years, if at all, and will require substantial additional capital to fund future operations.
XTX202 program investment was discontinued, leading to a $5.1 million decrease in costs for that specific program, indicating a pipeline reprioritization that resulted in a program termination.
The company's common stock bid price fell below Nasdaq's $1.00 minimum requirement, leading to a deficiency letter and transfer to the Nasdaq Capital Market, indicating potential investor concern and market volatility.

Risks

The company will need to obtain substantial additional capital in the future to finance operations and complete product candidate development, with no committed external sources of funds currently available.
Failure to regain and maintain compliance with Nasdaq's continued listing requirements could lead to delisting, negatively impacting stock price and access to capital markets.
The recently implemented 1-for-14 reverse stock split may not achieve its intended benefits, such as increasing per-share market price or attracting institutional investors, and could be viewed negatively by the market.
The business is highly dependent on the success of early-stage product candidates, which require significant additional preclinical and clinical development before regulatory approval and commercial launch.
The company's technological approach to masked immuno-oncology is unproven, and there is no guarantee of developing commercially valuable products.
Preclinical development is uncertain, and programs may experience delays or never advance to clinical trials, adversely affecting regulatory approvals or commercialization.
Substantial delays, termination, or suspension of clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
Product candidates may cause undesirable or unexpectedly severe side effects, potentially delaying or preventing regulatory approval, limiting commercial profiles, or resulting in negative consequences post-marketing approval.
Interim top-line and preliminary clinical trial data may change as more patient data become available and are subject to audit and verification, potentially leading to material changes in final data.
Reliance on third parties to conduct, supervise, and monitor IND-enabling studies and clinical trials poses risks if these parties perform unsatisfactorily.
Manufacturing biologics is complex, and problems could lead to delays or interruptions in supply; reliance on WuXi Biologics in China exposes the company to geopolitical and trade risks, including potential U.S. export control laws and sanctions (e.g., BIOSECURE Act).
Failure to obtain and maintain patent protection or if the scope of protection is insufficient, competitors could develop similar products, adversely affecting commercialization.
Reliance on in-license agreements for patent rights carries risks, including loss of rights if obligations are not met or inability to acquire necessary third-party intellectual property.
The regulatory approval process is expensive, time-consuming, and uncertain, with no guarantee of obtaining marketing approval for product candidates.
Unstable global economic and political conditions, including inflation, credit market instability, and geopolitical conflicts, could adversely affect business, financial condition, stock price, and ability to raise capital.
The company's ability to utilize net operating loss carryforwards and other tax attributes may be limited due to prior ownership changes (e.g., Section 382 of the Code) and potential regulatory changes.

Future Outlook

Xilio Therapeutics expects to continue incurring significant operating losses and negative operating cash flows for the foreseeable future as it advances its pipeline of novel, masked I-O molecules through preclinical and clinical development. The company anticipates its current cash and cash equivalents, along with recent financing, will fund operations through the end of 2027. Key milestones include submitting an IND for XTX501 in mid-2026, initiating a Phase 1 trial for XTX501 in H2 2026, reporting initial Phase 1 data for XTX501 in H2 2027, and submitting IND applications for wholly-owned masked T cell engager programs in 2027. The company also aims to deliver an option data package for efarindodekin alfa to Gilead in H1 2027 and continues to advance its AbbVie collaboration.

Management Comments

We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer.
Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents.
We believe XTX501 also has the potential to be a foundational backbone therapy for combination treatment with other agents.
We believe these clinical data support the best-in-class potential for vilastobart for use in combination therapies, and we are actively seeking a partner to maximize the value of vilastobart.
We believe our novel and proprietary platform technology and masking approach represent a meaningful competitive advantage in seeking to develop novel and highly effective treatments for cancer.
We anticipate that our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through the end of 2027.

Industry Context

StockSavvy.ai notes that Xilio Therapeutics operates in the highly competitive immuno-oncology space, characterized by rapid technological evolution and significant intellectual property emphasis. The company's focus on 'masked' I-O therapies aims to address the systemic toxicity limitations of current I-O agents, a critical unmet need in cancer treatment. While Xilio faces competition from major pharmaceutical and biotechnology companies with greater resources, its strategic collaborations with industry leaders like AbbVie and Gilead validate its masking technology platform. The regulatory landscape, particularly regarding biosimilars and drug pricing legislation like the Inflation Reduction Act, presents ongoing challenges for all companies in this sector, potentially impacting market access and profitability. The company's reliance on foreign CDMOs, specifically WuXi Biologics in China, introduces geopolitical risks, as highlighted by the BIOSECURE Act, which could disrupt supply chains and increase costs.

Comparison to Industry Standards

Xilio's efarindodekin alfa (masked IL-12) Phase 1 data showed it was generally well-tolerated at doses more than 100-fold greater than the maximum tolerated dose of recombinant human IL-12, suggesting a potentially improved safety profile compared to non-masked IL-12 agents, which are known for significant toxicity.
The reported partial responses in HPV-negative head and neck squamous cell carcinoma and uveal melanoma for efarindodekin alfa are encouraging, especially in tumor types historically resistant to immunotherapy, potentially differentiating it from existing or developing therapies.
For XTX501 (bispecific PD-1 / masked IL-2), the company notes that a third-party PD-1 / non-masked IL-2 bispecific antibody fusion protein has shown promising efficacy in immunotherapy-resistant NSCLC and cold tumors, implying XTX501 aims to build upon this with an improved safety profile due to masking.
Vilastobart (masked, Fc-enhanced anti-CTLA-4) is positioned against approved anti-CTLA-4 therapies like Yervoy (ipilimumab) and Imjudo (tremelimumab), aiming to offer a best-in-class profile with reduced systemic toxicity while maintaining efficacy in combination therapies for conditions like MSS metastatic CRC without liver metastases.
The company's strategy to develop masked T cell engagers targeting PSMA, STEAP1, and CLDN18.2 addresses targets where currently no T cell engager therapies are approved, potentially offering novel treatment options in areas with unmet needs, although non-masked T cell engagers for these targets are in development by competitors like Amgen, Astellas, and Regeneron.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and Chief Executive Officer	NA	Ren Russo	2026-01-01	Amended and Restated Employment Agreement
Chief Financial Officer and Chief Operating Officer	NA	Christopher Frankenfield	2024-08-03	Third Amended and Restated Employment Agreement
Senior Vice President, Finance and Accounting	NA	Kevin Brennan	2023-09-05	Employment Agreement
M.D.	NA	Katarina Luptakova	2023-09-05	Employment Agreement

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	Board of directors is divided into three classes with staggered three-year terms. Directors may be removed only for cause by an affirmative vote of at least 75% of stockholders. Vacancies are filled by a majority vote of directors then in office.	NA	Enhances board stability and makes hostile takeovers more difficult, potentially limiting stockholder influence over board composition.
Stockholder Action	Stockholders may not take any action by written consent in lieu of a meeting. Special meetings of stockholders can only be called by the Board of Directors.	NA	Restricts stockholder ability to initiate actions outside of scheduled meetings, potentially delaying actions favored by a majority of voting securities.
Bylaw and Certificate of Incorporation Amendments	Requires the affirmative vote of holders of at least 75% of the votes that all stockholders would be entitled to cast in an election of directors to amend or repeal certain provisions of the certificate of incorporation or bylaws.	NA	Establishes super-majority voting requirements, making it more difficult for stockholders to amend key corporate governance provisions.
Delaware Business Combination Statute	Subject to Section 203 of the DGCL, which prevents certain business combinations with interested stockholders for three years unless specific conditions are met.	NA	Acts as an anti-takeover provision, potentially discouraging unsolicited acquisition attempts.
Exclusive Forum Selection	Designates the Court of Chancery of the State of Delaware (or federal district court for the District of Delaware) as the sole and exclusive forum for certain corporate actions, and federal district courts for Securities Act claims.	NA	Aims to centralize litigation in specific forums, potentially reducing legal costs and inconsistent rulings, but may limit stockholders' choice of forum.
Director and Officer Liability	To the fullest extent permitted by Delaware law, no director or officer shall be personally liable to the Corporation (in the case of directors) or its stockholders (in the case of directors and officers) for monetary damages for any breach of fiduciary duty.	2025-06-10	Reduces personal liability risk for directors and officers, potentially aiding in attracting and retaining qualified individuals, but may limit recourse for stockholders in certain breach of duty cases.
Insider Trading Policy	Amended and Restated Insider Trading Policy, effective June 10, 2025, includes prohibitions on trading while aware of material nonpublic information, pledges, short sales, derivative, and hedging transactions. Also includes additional restrictions for 'Further Restricted Insiders' (directors, executive officers, designated employees) such as blackout periods and pre-clearance requirements.	2025-06-10	Strengthens internal controls against insider trading, promoting compliance with federal securities laws and protecting the company's reputation, but imposes stricter trading rules on key personnel.
Director Compensation Policy	Amended and Restated Director Compensation Policy, effective December 9, 2025, outlines annual cash retainers for board and committee service, and initial and annual equity awards (stock options) for non-employee directors, with specific vesting schedules and acceleration provisions.	2025-12-09	Aims to attract and retain outstanding director candidates by providing competitive compensation, aligning director interests with stockholders through equity, but increases stock-based compensation expense.

Legal Proceedings

The company is not currently a party to any material legal proceedings.

Related Party Transactions

AbbVie Inc. made a $10.0 million equity investment in Xilio Therapeutics' common stock in February 2025 as part of a collaboration, license, and option agreement.
Gilead Sciences, Inc. purchased $25.0 million of Xilio Therapeutics' common stock and prefunded warrants in three private placements during 2024 as part of an exclusive license agreement.

Stakeholder Impact

**Shareholders**: Potential for dilution from future capital raises and warrant exercises. Stock price volatility and Nasdaq listing compliance issues pose risks. However, strategic collaborations and pipeline progress offer potential for long-term value creation.
**Employees**: Workforce reduction in March 2024 impacted 15 employees (21% of workforce). Ongoing competition for qualified scientific and clinical personnel. Stock-based compensation plans aim to attract and retain talent.
**Customers/Patients**: Development of masked I-O therapies aims to provide improved outcomes for cancer patients with fewer severe side effects, addressing a significant unmet medical need.
**Collaborators (AbbVie, Gilead, Roche)**: Continued collaboration and milestone payments are crucial for funding and advancing product candidates. The success of these partnerships directly impacts the company's ability to develop and commercialize therapies.
**Creditors**: The company's significant operating losses and need for future capital raises could impact its creditworthiness, though current cash runway extends through 2027.

Next Steps

Submit an Investigational New Drug (IND) application for XTX501 (bispecific PD-1 / masked IL-2) in the middle of 2026.
Initiate a Phase 1 trial for XTX501 in the second half of 2026, subject to FDA clearance of the IND.
Report initial Phase 1 data for XTX501 in the second half of 2027.
Nominate a development candidate for the wholly-owned multi-specific, masked T cell engager targeting PSMA and STEAP1 in Q2 2026.
Advance the wholly-owned multi-specific, masked T cell engager targeting PSMA and STEAP1 into IND-enabling studies and submit an IND application in 2027.
Advance the wholly-owned masked T cell engager targeting CLDN18.2 into IND-enabling studies and submit an IND application in 2027.
Continue to advance the AbbVie collaboration toward key program milestones for both the masked antibody-based program and masked T cell engager program.
Continue to advance efarindodekin alfa (masked IL-12) through its ongoing Phase 2 clinical trial.
Deliver an option data package for efarindodekin alfa to Gilead in the first half of 2027.
Actively seek a partner to maximize the value of vilastobart (masked, Fc-enhanced anti-CTLA-4).
Regain compliance with Nasdaq's minimum bid price requirement by March 30, 2026, following the 1-for-14 reverse stock split.

Key Dates

Date	Description
2016-08-16	Xilio Development entered into an amended and restated exclusive license agreement with City of Hope for anti-CTLA-4 monoclonal antibody program.
2016-09-26	Company entered into a license agreement with WuXi Biologics (Hong Kong) Limited for anti-CTLA-4 monoclonal antibody program.
2017-12-01	Amendment to license agreement with WuXi Biologics (Hong Kong) Limited.
2019-08-26	Company entered into a facility lease agreement for its corporate headquarters in Waltham, Massachusetts.
2020-03-01	Rent commencement date for corporate headquarters lease.
2020-06-18	Xilio Therapeutics, Inc. was incorporated in Delaware.
2021-10-01	2020 Stock Incentive Plan, as amended, filed as Exhibit 10.1 to S-1.
2021-10-18	2021 Stock Incentive Plan and 2021 Employee Stock Purchase Plan became effective immediately prior to the IPO.
2021-10-22	Trading of common stock commenced on the Nasdaq Capital Market following the completion of the initial public offering.
2022-11-01	Company filed a universal shelf registration statement on Form S-3, which became effective on November 18, 2022.
2022-11-01	Company entered into a sales agreement with Cowen and Company LLC for at-the-market offerings.
2022-12-01	Congress eliminated provisions in FDCA and PHSA requiring animal testing in support of a BLA.
2022-12-01	FDORA passed, requiring sponsors to develop and submit a diversity action plan for Phase 3 clinical trials.
2023-07-01	Company and F. Hoffmann-La Roche Ltd (Roche) entered into a clinical trial collaboration to evaluate vilastobart in combination with atezolizumab.
2023-09-01	FDA issued draft guidance outlining terms of meetings between sponsors and FDA.
2023-09-05	Employment agreements for Kevin Brennan and Katarina Luptakova, M.D. became effective.
2023-12-01	FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures.
2024-03-01	Company announced a strategic portfolio reprioritization and restructuring, including a 21% workforce reduction.
2024-03-01	Xilio Development entered into an exclusive license agreement with Gilead Sciences, Inc. for efarindodekin alfa.
2024-03-01	Company entered into a stock purchase agreement with Gilead.
2024-04-01	Private placement with certain existing accredited investors closed, including issuance of common stock and prefunded warrants.
2024-08-03	Third Amended and Restated Employment Agreement for Christopher Frankenfield became effective.
2024-11-01	FASB issued ASU 2024-03, Income StatementReporting Comprehensive IncomeExpense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.
2024-11-12	2022 Inducement Stock Incentive Plan amended.
2024-12-01	FDA issued additional draft guidance relating to accelerated approval.
2025-01-01	HTA (Health Technology Assessment) regulation began to apply in the EU.
2025-01-01	FDA issued additional draft guidance relating to accelerated approval.
2025-01-27	FDA removed draft DAP guidance from its website in response to an executive order.
2025-02-10	Xilio Development entered into a collaboration, license and option agreement with AbbVie Group Holdings Limited.
2025-02-10	Company entered into a stock purchase agreement with AbbVie Inc.
2025-02-11	Private placement with AbbVie Inc. closed.
2025-02-14	Federal district court in Washington, D.C., embraced the reasoning of the Catalyst decision regarding orphan drug exclusivity.
2025-02-28	Patent portfolio status reported: 18 patent application families, 11 issued U.S. patents, 61 issued foreign patents, 164 pending foreign applications.
2025-03-01	2022 Inducement Stock Incentive Plan amended.
2025-03-01	Company filed a universal shelf registration statement on Form S-3 to register for sale up to $250.0 million of securities.
2025-03-01	Company entered into a new sales agreement with Leerink Partners, LLC for at-the-market offerings.
2025-04-01	Executive order directed HHS to take steps to reduce pharmaceutical product prices.
2025-04-04	Company received a deficiency letter from Nasdaq for closing bid price below $1.00.
2025-04-17	FDA appealed the federal district court decision regarding orphan drug exclusivity to the U.S. Court of Appeals for the D.C. Circuit.
2025-04-28	U.K. Parliament adopted amendments to improve and strengthen the U.K.'s clinical trials regulatory regime.
2025-05-01	Executive order called on pharmaceutical manufacturers to voluntarily reduce prices.
2025-05-08	Universal shelf registration statement on Form S-3 became effective.
2025-05-08	U.S. Court of Appeals for the Third Circuit rejected AstraZeneca L.P.'s challenge to the Medicare price negotiation program.
2025-05-21	FDA announced it would offer individual states the opportunity to submit draft proposals for pre-review of Section 804 Importation Programs.
2025-06-01	Company closed a follow-on offering of prefunded warrants and common stock warrants, receiving $47.0 million net proceeds.
2025-06-04	Council of the European Union adopted its position on the proposed overhaul of the EU general pharmaceutical legislative framework.
2025-06-10	Amendment to Restated Certificate of Incorporation became effective, exculpating executive officers.
2025-06-10	Insider Trading Policy amended and restated.
2025-06-17	U.S. Supreme Court dismissed the most recent judicial challenge to the PPACA.
2025-07-03	One Big Beautiful Bill Act (OBBBA) signed into law, extending orphan drug exemption to drugs with multiple orphan designations.
2025-07-14	Current administration began layoffs across HHS, including at the FDA, following litigation reaching the U.S. Supreme Court.
2025-07-27	Pursuant to a court order, the FDA restored the draft DAP guidance to its website.
2025-07-31	17 pharmaceutical companies issued letters reiterating May 2025 executive order requirements and demanding MFN pricing to Medicaid patients.
2025-08-22	Company received a second deficiency notice from Nasdaq for not being in compliance with the minimum $10.0 million stockholders' equity requirement.
2025-09-02	Data cutoff date for Phase 1 monotherapy dose escalation of efarindodekin alfa.
2025-09-09	Current administration issued a memorandum directing HHS to ensure transparency and accuracy in direct-to-consumer prescription drug advertising.
2025-09-21	FDA published final regulations describing types of evidence for determining intended use of a drug or biologic.
2025-09-23	FDA issued draft guidance outlining considerations for relying on confirmatory evidence in lieu of a second clinical study.
2025-09-25	U.S. administration announced that, beginning October 1, 2025, all branded or patented drugs imported in the U.S. would face a 100% tariff.
2025-10-01	Initial period to regain compliance with Nasdaq minimum bid price requirement ended.
2025-10-01	Federal government shut down for 43 days.
2025-10-02	Company received letter from Nasdaq approving application to list securities on the Nasdaq Capital Market.
2025-10-06	Securities transferred to the Nasdaq Capital Market.
2025-10-01	FDA issued draft guidance proposing to eliminate the need for comparative human clinical efficacy studies for biosimilar products.
2025-10-01	FDA issued internal guidance clarifying materially incomplete or inadequately organized applications will be subject to an RTF.
2025-10-01	FDA issued final guidance with updated recommendations for GCPs.
2025-10-01	FDA issued final guidance focusing on patient-focused drug development.
2025-10-20	2025 Stock Incentive Plan filed as Appendix A to DEF 14A.
2025-11-01	Company announced Phase 1 data for efarindodekin alfa at the Society for Immunotherapy of Cancer 40th Annual Meeting.
2025-11-18	2022 Inducement Stock Incentive Plan adopted by the Board.
2025-11-21	Stockholders adopted the 2025 Stock Incentive Plan.
2025-11-21	Stock option repricing became effective upon stockholder approval.
2025-12-01	Series A warrants became exercisable.
2025-12-02	Series B warrants qualified for equity classification due to settlement of exercise price reset feature.
2025-12-09	Amended and Restated Director Compensation Policy became effective.
2025-12-11	European Parliament and Council reached a provisional political agreement on EU pharmaceutical legislation.
2025-12-18	Chairs of multiple Senate and House committees sent a letter to the Department of Defense recommending WuXi AppTec, WuXi Biologics, and WuXi XDC be added to the 1260H list.
2025-12-19	EC renewed decision that the U.K.'s data protection level is adequate for data transfer from the EU to the U.K. until December 27, 2031.
2025-12-23	CMS proposed two five-year pilot programs (GLOBE and GUARD) to implement a reference pricing regime for drugs under Medicare.
2025-12-31	Fiscal year ended. 1,319,145 Series B warrants and 1,319,145 Series C warrants expired.
2026-01-01	Negotiated prices for ten selected drug products under Medicare Drug Price Negotiation Program became effective.
2026-01-01	Number of shares reserved for issuance under the 2021 Plan automatically increased by 226,931 shares.
2026-01-01	Number of shares reserved for issuance under the 2021 ESPP increased by 41,718 shares.
2026-01-01	Amended and Restated Employment Agreement for Ren Russo became effective.
2026-01-20	Second Amended and Restated 2022 Inducement Stock Incentive Plan became effective.
2026-01-27	CMS published the list of 15 drugs selected for the third cycle of Medicare price negotiations.
2026-01-31	FDA issued eight notices of non-compliance regarding clinicaltrials.gov reporting requirements.
2026-02-01	Company closed a follow-on offering of prefunded warrants, receiving $37.3 million net proceeds.
2026-02-05	Administration launched a website directing individuals to pharmaceutical manufacturer websites offering price discounts.
2026-02-23	Stockholders voted to adopt and approve an amendment to the restated certificate of incorporation to effect a reverse stock split.
2026-02-28	Patent portfolio status reported.
2026-03-12	Company filed a certificate of amendment to its restated certificate of incorporation to effect a 1-for-14 reverse stock split.
2026-03-13	1-for-14 reverse stock split became effective at 5:00 p.m. Eastern Time.
2026-03-16	Number of shares of common stock outstanding was 5,782,511.
2026-03-23	Annual Report on Form 10-K filed.
2026-03-30	Deadline to regain compliance with Nasdaq minimum bid price requirement.
2026-06-01	Series C warrants become exercisable.
2026-06-30	Tranche 2 Measurement Date for stock options.
2026-10-01	Proposed effective date for GLOBE and GUARD pilot programs for Medicare drug pricing.
2026-12-02	Series C warrants expire.
2026-12-31	Expected end of Emerging Growth Company status. Tranche 2 Measurement Date for stock options. Tranche 4 Measurement Date for stock options.
2027-01-01	Negotiated prices for second set of 15 drugs under Medicare Drug Price Negotiation Program become effective.
2027-06-30	Tranche 2 Measurement Date for stock options.
2027-12-31	Expected period through which existing cash and cash equivalents will fund operating expenses and capital expenditure requirements. Tranche 2 Measurement Date for stock options.
2028-01-01	Negotiated prices for third set of 15 drugs under Medicare Drug Price Negotiation Program become effective.
2028-06-30	Tranche 2 Measurement Date for stock options.
2029-01-01	Negotiated prices for 20 Part B or Part D drugs under Medicare Drug Price Negotiation Program become effective.
2029-06-30	Tranche 2 Measurement Date for stock options.
2030-03-01	Operating lease for corporate headquarters expires.
2030-06-05	Series A warrants expire.
2030-06-30	Tranche 2 Measurement Date for stock options.
2031-12-31	Medicare payment reductions of up to 2% per fiscal year remain in effect.

Recommendation

hold

Xilio Therapeutics has demonstrated positive momentum with a significant reduction in net losses and a substantial increase in collaboration revenue, validating its technology through partnerships with AbbVie and Gilead. The extended cash runway through 2027 provides crucial operational stability. However, the company remains in early clinical stages with no products approved for commercial sale, facing inherent risks of drug development, intense competition, and regulatory uncertainties, including Nasdaq listing compliance. The potential for future capital raises and the impact of the reverse stock split introduce additional variables. Given the promising pipeline advancements and strategic collaborations balanced against the high-risk nature of clinical-stage biotech and ongoing financial needs, a 'hold' recommendation is appropriate for investors to monitor further clinical data and financial execution.

Keywords

Immuno-oncology, Masked biologics, Cancer therapy, XTX501, Efarindodekin alfa, Vilastobart, T cell engager, PD-1, IL-2, IL-12, CTLA-4, PSMA, STEAP1, CLDN18.2, Clinical trials, Preclinical development, Biotechnology, SEC filing, 10-K, Nasdaq, AbbVie, Gilead, WuXi Biologics, Orphan drug, Intellectual property, Capital raise

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.